Contact Us
Portal Login
  1. Home
  2. Amnio-Maxx®

Description and Intended Use

Amnio-Maxx® is a family of amnion patch allografts intended for use as a protective barrier from the surrounding environment for acute and chronic wounds. Examples include diabetic ulcers, venous ulcers, surgical wounds (post-Mohs surgery, post-laser surgery, podiatric wounds, wound dehiscence), chronic vascular ulcers, pressure and non-pressure ulcers, tunneled/undermined wounds, trauma wounds (partial thickness burns, abrasions, skin tears, lacerations), and draining wounds. Amnio-Maxx Dual Layer Amnion Patch may be applied from the onset of the wound and for the duration of the wound, weekly or at the discretion of the health care practitioner.

Clinically Relevant Features

DUAL-LAYER

Dual-layer design is intended to provide increased thickness and durability.

DESIGNED TO SUPPORT EASE OF USE

Increased thickness may support improved handling characteristics during surgical procedures and wound management.

SURGICAL BARRIER

Designed for use as a protective covering and barrier in surgical procedures and wound management.

DESIGNED TO SUPPORT EASE OF PLACEMENT

Dual-layer configuration is designed to support flexible placement without strict orientation requirements.

Ordering Information

  • Code Description
  • AMM-22 AmnioMaxx 2cm x 2cm
  • AMM-24 AmnioMaxx 2cm X 4cm
  • AMM-44AmnioMaxx 4cm X 4cm
  • AMM-48 AmnioMaxx 4cm X 8cm

REFERENCES

1. Spoerl, E.; Wollensak, G.; Reber, F.; Pillunat, L. Cross-linking of human amniotic membrane by glutaraldehyde. {\em Ophthalmic Res.} {2004}, {\em 36}, 71–77. https://doi.org/10.1159/000075648 Reference discusses the physical and structural properties of amniotic membrane following cross-linking.
2. Niknejad, H.; Peirovi, H.; Jorjani, M.; Ahmadiani, A.; Ghanavi, J.; Seifalian, A.M. Properties of the amniotic membrane for potential use in tissue engineering. {\em Eur. Cell Mater.} {2008}, {\em 15}, 88–99. https://doi.org/10.22203/eCM.v015a07
3. Mamede, A.C.; Carvalho, M.J.; Abrantes, A.M.; Laranjo, M.; Maia, C.J.; Botelho, M.F. Amniotic membrane: From structure and functions to clinical applications. {\em Cell Tissue Res.} {2012}, {\em 349}, 447–458. https://doi.org/10.1007/s00441-012-1424-6* *Published literature describes general structural and compositional characteristics of human amniotic membrane.
*A prospective clinical study evaluating the effect of Amnio-Maxx® on chronic diabetic foot ulcers is currently ongoing. Study Title: Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers. ClinicalTrials.gov Identifier: NCT07209475
Results are pending

Explore our Entire Product Line

Autologous Advanced Biologics

Cellular Bone Graft

Traditional Bone Grafts

Advanced Synthetics

Wound Care

About Royal

Royal is a pioneering leader in orthobiologic and wound care research and development. Royal’s commitment lies in delivering top-tier, innovative biologic solutions that enhance the healing process and improve patients' quality of life. Royal places patient well-being at the center of its mission, offering exceptional solutions to address a variety of complex needs.

At Royal, our mission is driven by patient-centered care, innovation and excellence, and integrity and compassion.
Royal provides a comprehensive array of products tailored to meet the varied needs of the orthobiologic and wound care industry.

As a rapidly expanding force in the industry, Royal is continuously developing and launching new products and solutions that set benchmarks for quality, effectiveness, and patient outcomes. Royal’s commitment to research and innovation keeps it at the forefront of the industry, helping to shape the future of healthcare and improving lives.